CAR T cells targeting CD19 have especially been impressive in the treatment of ALL, with clinical response rates of up to 90% in paediatric B‐cell ALL patients (Grupp et al, 2013; Maude et al, 2014). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.